Literature DB >> 24997711

Sports in LCHAD Deficiency: Maximal Incremental and Endurance Exercise Tests in a 13-Year-Old Patient with Long-Chain 3-Hydroxy Acyl-CoA Dehydrogenase Deficiency (LCHADD) and Heptanoate Treatment.

D Karall1, G Mair, U Albrecht, K Niedermayr, T Karall, W Schobersberger, S Scholl-Bürgi.   

Abstract

Exercise and subsequent catabolism is a potential trigger for creatine kinase (CK) concentration increase (rhabdomyolysis) in patients with LCHADD, therefore we evaluated the clinical and biochemical stability under physical exertion conditions at the age of 13 years in a currently 14-year-old LCHADD patient treated with heptanoate.LCHADD was diagnosed during first decompensation at age 20 months. In the following 2 years, the patient had several episodes of rhabdomyolysis. Heptanoate 0.5-1 g/kg/day was started at 4 years, with no further CK elevations since. He is clinically stable, has retinopathy without vision impairment or polyneuropathy. Maximal incremental and endurance exercise tests were performed to evaluate both clinical and metabolic stability during and after exertion.Physical fitness was adequate for age (maximum blood lactate 7.0 mmol/L, appropriate lactate performance curve, maximum heart rate of 196 bpm, maximum power 139 Watt = 2.68 Watt/kg body weight). There were no signs of clinical (muscle pain, dark urine) or metabolic derangement (stable CK, acyl carnitine profiles, blood gas analyses) - neither after maximal incremental nor endurance exertion.This case illustrates that both under maximal incremental and endurance exertion, clinical and biochemical parameters remained stable in this currently 14-year-old LCHADD patient receiving heptanoate treatment.

Entities:  

Year:  2014        PMID: 24997711      PMCID: PMC4241206          DOI: 10.1007/8904_2014_313

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  16 in total

Review 1.  Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting.

Authors:  Martin Lindner; Georg F Hoffmann; Dietrich Matern
Journal:  J Inherit Metab Dis       Date:  2010-04-07       Impact factor: 4.982

2.  Clinical stress testing in the pediatric age group: a statement from the American Heart Association Council on Cardiovascular Disease in the Young, Committee on Atherosclerosis, Hypertension, and Obesity in Youth.

Authors:  Stephen M Paridon; Bruce S Alpert; Steven R Boas; Marco E Cabrera; Laura L Caldarera; Stephen R Daniels; Thomas R Kimball; Timothy K Knilans; Patricia A Nixon; Jonathan Rhodes; Angela T Yetman
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

3.  Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency.

Authors:  Melanie B Gillingham; Bradley Scott; Diane Elliott; Cary O Harding
Journal:  Mol Genet Metab       Date:  2006-07-27       Impact factor: 4.797

4.  Refined staging for chorioretinopathy in long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency.

Authors:  Tiina Tyni; Tuuli Immonen; Päivi Lindahl; Anna Majander; Tero Kivelä
Journal:  Ophthalmic Res       Date:  2012       Impact factor: 2.892

5.  Substrate oxidation and cardiac performance during exercise in disorders of long chain fatty acid oxidation.

Authors:  Annie M Behrend; Cary O Harding; James D Shoemaker; Dietrich Matern; David J Sahn; Diane L Elliot; Melanie B Gillingham
Journal:  Mol Genet Metab       Date:  2011-10-01       Impact factor: 4.797

6.  EFFECT OF FEEDING, EXERCISE AND GENOTYPE ON PLASMA 3-HYDROXYACYLCARNITINES IN CHILDREN WITH LCHAD DEFICIENCY.

Authors:  Melanie B Gillingham; Dietrich Matern; Cary O Harding
Journal:  Top Clin Nutr       Date:  2009-10       Impact factor: 0.508

Review 7.  Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential.

Authors:  Charles R Roe; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

8.  Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats.

Authors:  Renée P Kinman; Takhar Kasumov; Kathryn A Jobbins; Katherine R Thomas; Jillian E Adams; Lisa N Brunengraber; Gerd Kutz; Wolf-Ulrich Brewer; Charles R Roe; Henri Brunengraber
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-05-16       Impact factor: 4.310

9.  Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy.

Authors:  C R Roe; B-Z Yang; H Brunengraber; D S Roe; M Wallace; B K Garritson
Journal:  Neurology       Date:  2008-07-22       Impact factor: 9.910

10.  A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency.

Authors:  Georgianne L Arnold; Johan Van Hove; Debra Freedenberg; Arnold Strauss; Nicola Longo; Barbara Burton; Cheryl Garganta; Can Ficicioglu; Stephen Cederbaum; Cary Harding; Richard G Boles; Dietrich Matern; Pranesh Chakraborty; Annette Feigenbaum
Journal:  Mol Genet Metab       Date:  2009-01-20       Impact factor: 4.797

View more
  8 in total

1.  Higher dietary protein intake preserves lean body mass, lowers liver lipid deposition, and maintains metabolic control in participants with long-chain fatty acid oxidation disorders.

Authors:  Melanie B Gillingham; Gabriela Elizondo; Annie Behrend; Dietrich Matern; Dale A Schoeller; Cary O Harding; Jonathan Q Purnell
Journal:  J Inherit Metab Dis       Date:  2019-07-24       Impact factor: 4.982

2.  Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD.

Authors:  Gabriela Elizondo; Dietrich Matern; Jerry Vockley; Cary O Harding; Melanie B Gillingham
Journal:  Mol Genet Metab       Date:  2020-09-06       Impact factor: 4.797

3.  Management of an LCHADD Patient During Pregnancy and High Intensity Exercise.

Authors:  D C D van Eerd; I A Brussé; V F R Adriaens; R T Mankowski; S F E Praet; M Michels; M Langeveld
Journal:  JIMD Rep       Date:  2016-06-23

4.  Clinical outcome, biochemical and therapeutic follow-up in 14 Austrian patients with Long-Chain 3-Hydroxy Acyl CoA Dehydrogenase Deficiency (LCHADD).

Authors:  Daniela Karall; Michaela Brunner-Krainz; Katharina Kogelnig; Vassiliki Konstantopoulou; Esther M Maier; Dorothea Möslinger; Barbara Plecko; Wolfgang Sperl; Barbara Volkmar; Sabine Scholl-Bürgi
Journal:  Orphanet J Rare Dis       Date:  2015-02-22       Impact factor: 4.123

5.  Fatal pitfalls in newborn screening for mitochondrial trifunctional protein (MTP)/long-chain 3-Hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency.

Authors:  Amelie S Lotz-Havla; Wulf Röschinger; Katharina Schiergens; Katharina Singer; Daniela Karall; Vassiliki Konstantopoulou; Saskia B Wortmann; Esther M Maier
Journal:  Orphanet J Rare Dis       Date:  2018-07-20       Impact factor: 4.123

6.  Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders.

Authors:  Sabine Scholl-Bürgi; Daniela Karall; Thomas Zöggeler; Katharina Stock; Monika Jörg-Streller; Johannes Spenger; Vassiliki Konstantopoulou; Miriam Hufgard-Leitner
Journal:  Orphanet J Rare Dis       Date:  2021-01-14       Impact factor: 4.123

7.  A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome.

Authors:  Pasquale Striano; Stéphane Auvin; Abigail Collins; Rita Horvath; Ingrid E Scheffer; Michal Tzadok; Ian Miller; Mary Kay Koenig; Adrian Lacy; Ronald Davis; Angela Garcia-Cazorla; Russell P Saneto; Melanie Brandabur; Susan Blair; Tony Koutsoukos; Darryl De Vivo
Journal:  Epilepsia       Date:  2022-05-21       Impact factor: 6.740

8.  Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.

Authors:  Jerry Vockley; Barbara Burton; Gerard Berry; Nicola Longo; John Phillips; Amarilis Sanchez-Valle; Kimberly Chapman; Pranoot Tanpaiboon; Stephanie Grunewald; Elaine Murphy; Xiaoxiao Lu; Jason Cataldo
Journal:  J Inherit Metab Dis       Date:  2020-09-14       Impact factor: 4.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.